Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 23, 2009

Marinomed to Mine Bioalvo’s Library of Marine Extracts for Drug Candidates

  • Marinomed Biotechnologie negotiated access to Portuguese firm Bioalvo’a PharmaBUG library of natural marine extracts for drug discovery. Marinomed will have exclusive rights to use its own screening platform for identifying compounds in PharmaBUG that have potential therapeutic utility in immunology and infectious diseases.

    Based in Vienna, Marinomed is focused on marine organisms as a source of new therapeutics. The company is exploiting its Imuvirex® discovery platform to allow the selection of candidates against viral and immune targets. The company’s current pipeline includes natural, mainly marine-derived compounds for the treatment of respiratory illnesses and immunological disorders.  The lead product, MAM-06.301, is currently in Phase II development for treating allergy.

    Marinomed’s marketed product is the antiviral Carragelose®, launched in the EU in 2008, as the nasal spray, Coldamaris®, for the prevention and treatment of colds and viral-induced respiratory infections. The firm says that Carragelose is also being investigated for other indications.

    In March Marinomed obtained global license and sublicensing rights from PharmaMar to analogs of kahalalide F, for applications outside the fields of oncology and neurology.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »